Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors.

Standard

Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. / Solakoglu, Oender; Maierhofer, Christine; Lahr, Georgia; Breit, Elisabeth; Scheunemann, Peter; Heumos, Isabella; Pichlmeier, Uwe; Schlimok, Gunter; Oberneder, Ralph; Kollermann, Manfred W; Köllermann, Jens; Speicher, Michael R; Pantel, Klaus.

in: P NATL ACAD SCI USA, Jahrgang 99, Nr. 4, 4, 2002, S. 2246-2251.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Solakoglu, O, Maierhofer, C, Lahr, G, Breit, E, Scheunemann, P, Heumos, I, Pichlmeier, U, Schlimok, G, Oberneder, R, Kollermann, MW, Köllermann, J, Speicher, MR & Pantel, K 2002, 'Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors.', P NATL ACAD SCI USA, Jg. 99, Nr. 4, 4, S. 2246-2251. <http://www.ncbi.nlm.nih.gov/pubmed/11854519?dopt=Citation>

APA

Solakoglu, O., Maierhofer, C., Lahr, G., Breit, E., Scheunemann, P., Heumos, I., Pichlmeier, U., Schlimok, G., Oberneder, R., Kollermann, M. W., Köllermann, J., Speicher, M. R., & Pantel, K. (2002). Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. P NATL ACAD SCI USA, 99(4), 2246-2251. [4]. http://www.ncbi.nlm.nih.gov/pubmed/11854519?dopt=Citation

Vancouver

Solakoglu O, Maierhofer C, Lahr G, Breit E, Scheunemann P, Heumos I et al. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. P NATL ACAD SCI USA. 2002;99(4):2246-2251. 4.

Bibtex

@article{c67c4ebb968f46739102cb0c68c26dce,
title = "Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors.",
abstract = "Bone marrow is a major homing site for circulating epithelial tumor cells. The present study was aimed to assess the proliferative capacity of occult metastatic cells in bone marrow of patients with operable solid tumors especially with regard to their clinical outcome. We obtained bone marrow aspirates from 153 patients with carcinomas of the prostate (n = 46), breast (n = 45), colon (n = 33), and kidney (n = 29). Most of the patients (87%) had primary disease with no clinical signs of overt metastases [tumor-node-metastasis (TNM)-stage UICC (Union Internationale Contre le Cancer) I-III]. After bone marrow was cultured for 21-102 days under special cell culture conditions, viable epithelial cells were detected by cytokeratin staining in 124 patients (81%). The cultured epithelial cells harbored Ki-ras2 mutations and numerical chromosomal aberrations. The highest median number of expanded tumor cells was observed in prostate cancer (2,619 per flask). There was a significant positive correlation between the number of expanded tumor cells and the UICC-stage of the patients (P = 0.03) or the presence of overt metastases (P = 0.04). Moreover, a strong expansion of tumor cells was correlated to an increased rate of cancer-related deaths (P = 0.007) and a reduced survival of the patients (P = 0.006). In conclusion, the majority of cancer patients have viable tumor cells in their bone marrow at primary tumor diagnosis, and the proliferative potential of these cells determines the clinical outcome.",
author = "Oender Solakoglu and Christine Maierhofer and Georgia Lahr and Elisabeth Breit and Peter Scheunemann and Isabella Heumos and Uwe Pichlmeier and Gunter Schlimok and Ralph Oberneder and Kollermann, {Manfred W} and Jens K{\"o}llermann and Speicher, {Michael R} and Klaus Pantel",
year = "2002",
language = "Deutsch",
volume = "99",
pages = "2246--2251",
journal = "P NATL ACAD SCI USA",
issn = "0027-8424",
publisher = "National Academy of Sciences",
number = "4",

}

RIS

TY - JOUR

T1 - Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors.

AU - Solakoglu, Oender

AU - Maierhofer, Christine

AU - Lahr, Georgia

AU - Breit, Elisabeth

AU - Scheunemann, Peter

AU - Heumos, Isabella

AU - Pichlmeier, Uwe

AU - Schlimok, Gunter

AU - Oberneder, Ralph

AU - Kollermann, Manfred W

AU - Köllermann, Jens

AU - Speicher, Michael R

AU - Pantel, Klaus

PY - 2002

Y1 - 2002

N2 - Bone marrow is a major homing site for circulating epithelial tumor cells. The present study was aimed to assess the proliferative capacity of occult metastatic cells in bone marrow of patients with operable solid tumors especially with regard to their clinical outcome. We obtained bone marrow aspirates from 153 patients with carcinomas of the prostate (n = 46), breast (n = 45), colon (n = 33), and kidney (n = 29). Most of the patients (87%) had primary disease with no clinical signs of overt metastases [tumor-node-metastasis (TNM)-stage UICC (Union Internationale Contre le Cancer) I-III]. After bone marrow was cultured for 21-102 days under special cell culture conditions, viable epithelial cells were detected by cytokeratin staining in 124 patients (81%). The cultured epithelial cells harbored Ki-ras2 mutations and numerical chromosomal aberrations. The highest median number of expanded tumor cells was observed in prostate cancer (2,619 per flask). There was a significant positive correlation between the number of expanded tumor cells and the UICC-stage of the patients (P = 0.03) or the presence of overt metastases (P = 0.04). Moreover, a strong expansion of tumor cells was correlated to an increased rate of cancer-related deaths (P = 0.007) and a reduced survival of the patients (P = 0.006). In conclusion, the majority of cancer patients have viable tumor cells in their bone marrow at primary tumor diagnosis, and the proliferative potential of these cells determines the clinical outcome.

AB - Bone marrow is a major homing site for circulating epithelial tumor cells. The present study was aimed to assess the proliferative capacity of occult metastatic cells in bone marrow of patients with operable solid tumors especially with regard to their clinical outcome. We obtained bone marrow aspirates from 153 patients with carcinomas of the prostate (n = 46), breast (n = 45), colon (n = 33), and kidney (n = 29). Most of the patients (87%) had primary disease with no clinical signs of overt metastases [tumor-node-metastasis (TNM)-stage UICC (Union Internationale Contre le Cancer) I-III]. After bone marrow was cultured for 21-102 days under special cell culture conditions, viable epithelial cells were detected by cytokeratin staining in 124 patients (81%). The cultured epithelial cells harbored Ki-ras2 mutations and numerical chromosomal aberrations. The highest median number of expanded tumor cells was observed in prostate cancer (2,619 per flask). There was a significant positive correlation between the number of expanded tumor cells and the UICC-stage of the patients (P = 0.03) or the presence of overt metastases (P = 0.04). Moreover, a strong expansion of tumor cells was correlated to an increased rate of cancer-related deaths (P = 0.007) and a reduced survival of the patients (P = 0.006). In conclusion, the majority of cancer patients have viable tumor cells in their bone marrow at primary tumor diagnosis, and the proliferative potential of these cells determines the clinical outcome.

M3 - SCORING: Zeitschriftenaufsatz

VL - 99

SP - 2246

EP - 2251

JO - P NATL ACAD SCI USA

JF - P NATL ACAD SCI USA

SN - 0027-8424

IS - 4

M1 - 4

ER -